Skip to Content

Frequently Searched

Supported by

Medically Integrated Dispensing of Regorafenib for Metastatic Colorectal Cancer Patients

Download PQI pdf 3.31MB

Last Updated: June 1, 2020

By: Tennessee Oncology, TN | Texas Oncology, TX

About this PQI in Action

By adopting NCODA’s PQI resource tools, a peer-reviewed guidance for effective practices that improve knowledge exchange within a medically integrated dispensing (MID) pharmacy team and result in positive patient outcomes. This article will examine examples of common barriers within these treatment settings and provide suggestions to improve outcomes for metastatic colorectal cancer (mCRC) patients receiving Stivarga® (regorafenib) therapy.

More About This PQI in Action

Find a PQI

Treatment Support Kit

Treatment Support Kit: Regorafenib

Last Updated: January 1, 2025

PQI

 PQI: Regorafenib (Stivarga®) in Metastatic Colorectal Cancer

Last Updated: October 19, 2023

PQI

 PQI: Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma

Last Updated: October 13, 2023

PQI

 PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Last Updated: October 10, 2023

PQI in Action

PQI in Action: Multidisciplinary Management of Metastatic Colorectal Cancer Patients within Medically Integrated Pharmacy Practices

Last Updated: November 1, 2019